NASDAQ · INXB
Inhibrx Biosciences, Inc.
Healthcare · Biotechnology
$15.86
Up+$1.94 (+13.94%)
Updated Sep 10, 2026, 7:32 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 225.87M
- P/E ratio
- -8.2
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 725.34K
- Avg. volume
- 507.57K
Price performance
INXB price history
1M range · 0 trading sessions · Daily adjusted prices
INXB does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest INXB news
The latest Smart Investors Daily articles mentioning INXB.
Stock researchCompany · Overview
INXB research
Overview
Company profile and research snapshot.
Company profile
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
